CRISPRing T Cell Therapeutics: What Are The Benefits?

CAR-T cells are part of the new arsenal of revolutionary immunotherapeutics, which have radically changed cancer treatment. These genetically engineered T cells are modified to express novel “Chimeric Antigen Receptors” or CARs, endowing them with unique tumor-killing properties. CAR-T cell therapy has been particularly effective in the treatment of patients with hematological malignancies. In contrast, for solid tumors, inhibitory mechanisms within the tumor microenvironment have hampered their effectiveness. Thus strategies enabling precise and multiplex editing are being leveraged to engineer more effective T cell medicines.

CAR-T Cell Therapy: An Overview. The workflow for developing CAR-T cells for autologous therapy starts by obtaining T cells from the patient through leukapheresis, followed by CAR sequence delivery into activated T cells commonly by viral transduction, expansion of engineered T cells, and infusion of T cell medicine into the patient. Modified from “CAR-T Cell Therapy: An Overview” by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates.

You could check the full content here.